Search all articles within the Institute for Biomedicine and Glycomics topic
Pictured left to right: Professor Michael Good AO, PDG Sandy Doumany OAM, Associate Professor Danielle Stanisic, Her Excellency the Honourable...
A clinical trial to test the efficacy and safety of the transplantation of nasal cells to treat chronic spinal cord...
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine composition designed to be administered via the nose.
A Phase I human clinical trial is set to commence to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.
Salivary biomarkers could be the way forward in diagnosing liver fibrosis thanks to a partnership between Griffith University and Gallipoli...
A world-first trial to help improve the lives of Australians living with a debilitating spinal cord injury is a step closer with a $6.8 million Medical Research Future Fund grant.
A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic.
Professor Paul Clarke will join the University as the inaugural Executive Director of the new Institute for Biomedicine and Glycomics.
A $2 million grant awarded to establish the Queensland Drug Discovery Alliance (QDDA) will align and grow Queensland’s small molecule therapeutic discovery capability under the leadership of Therapeutic Innovation Australia (TIA).
In a groundbreaking effort to combat the devastating effects of Spinal Muscular Atrophy (SMA), Dr. Jean Giacomotto from the Griffith...
